Cefuroxime Use in Children with Abdominal Pain

Introduction to Cefuroxime Use

The Infectious Diseases Society of America recommends cefuroxime for mild-to-moderate community-acquired complicated intra-abdominal infections (in combination with metronidazole) or community-acquired acute cholecystitis of mild-to-moderate severity 1, 2

For mild-to-moderate community-acquired intra-abdominal infections, cefuroxime can be used in combination with metronidazole, providing coverage against enteric gram-negative aerobic and facultative bacilli, enteric gram-positive streptococci, and obligate anaerobic bacilli 3, 4
The combination regimen is appropriate for distal small bowel, appendiceal, and colon-derived infections 3
For community-acquired acute cholecystitis of mild-to-moderate severity, cefuroxime is an acceptable single-agent option 2

Routine broad-spectrum antibiotics, including cefuroxime, are NOT indicated for children with fever and abdominal pain when there is low suspicion of complicated intra-abdominal infection 6
Cefuroxime is NOT recommended for high-severity community-acquired infections, which require broader coverage with agents like cefepime, ceftazidime, ciprofloxacin, or levofloxacin, each combined with metronidazole 3, 4

Advanced-generation cephalosporins are preferred over cefuroxime for pediatric complicated intra-abdominal infections 1, 5
Recommended regimens include: cefotaxime, ceftriaxone, ceftazidime, or cefepime with metronidazole 1, 5

Antimicrobial therapy alone is insufficient for complicated intra-abdominal infections, and surgical intervention or drainage must be performed when indicated as an adjunct to antibiotic therapy 4
Continue antibiotics for a minimum of 48-72 hours after the patient becomes asymptomatic or after bacterial eradication is obtained 7
Therapy should not exceed what is necessary, as prolonged therapy increases the risk of C. difficile colitis, superinfection, and resistance 7

Do not use cefuroxime without metronidazole for intra-abdominal infections involving the distal small bowel, appendix, or colon, as anaerobic coverage is essential 3
Do not use cefuroxime for healthcare-associated infections or when there is concern for resistant organisms; broader spectrum agents are required 2
Do not continue antibiotics beyond resolution of clinical signs of infection, as this promotes resistance and complications 7
Do not rely on antibiotics alone when source control (surgery/drainage) is indicated 4